Hemp/CBD and other cannabis startups share in equity deal count quarterly 2018-2019
In the second quarter of 2019, startups focusing on hemp and cannabidiol accounted for 25 percent of the number of equity deals including cannabis startups. The statistic illustrates the share of the global equity deal count including cannabis startups from 1st quarter 2014 to 2nd quarter 2019, by type/focus. Hemp-derived cannabidiol (CBD) is among the most promising compounds of cannabis. CBD has no psychoactive effects and could possibly be used in the treatment of anxiety, cognition, movement disorders, and pain.